MedPage Today news story
Children with HIV on dolutegravir-based antiretroviral therapy can safely receive the standard prophylactic TB treatment without needing to up their dolutegravir dose, the phase I/II DOLPHIN-KIDS study suggested.
Among 41 children who received a single dose of dolutegravir plus two nucleoside reverse transcriptase inhibitors (NRTIs) and the standard TB treatment of rifapentine and isoniazid, 95% remained virally suppressed and dolutegravir trough concentrations dropped below the predetermined threshold of 64 ng/mL in only two children.
Read the full news story here.
View all MedPage Today reports from CROI 2026
Source : MedPage Today
Related HIV and Co-Infections News
-
[CROI 2026] aidsmap: Bictegravir/lenacapavir combination pill could be an option for people taking complex regimens
-
[CROI 2026] [Press release] Merck announces late-breaking data from three Phase 3 trials evaluating doravirine/islatravir, an investigational, once-daily, two-drug regimen for the treatment of adults living with HIV-1
-
[CROI 2026] Life4me+: Doravirine/islatravir for initial HIV therapy: A two-drug strategy in a three-drug world
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.